Literature DB >> 1350490

Left ventricular hypertrophy regression during antihypertensive treatment.

H Eichstaedt1, O Danne, R J Schroeder, D Kreuz.   

Abstract

For more than 20 years hypertrophy regression has been in the focus of hypertension research. Many studies in animals have shown impressive reduction of left ventricular hypertrophy after medical treatment of hypertension. The most important result seems to be that hypertrophy can be almost completely reversed in young animals, whereas in older animals regression of left ventricular hypertrophy appears to be less complete. Hypertrophy regression in man seems much more difficult to prove. The direct correlation between left ventricular muscle mass and ECG changes has been disappointing in many studies. Echocardiography is able to show a comparatively good impression of left ventricular muscle mass and therefore can also demonstrate regression of left ventricular hypertrophy within its methodological limits. There is no doubt that today magnetic resonance imaging has by far the best imaging quality of all the clinical methods and is able to demonstrate both hypertrophy and its regression with incomparable accuracy. In the present clinical study hypertrophy regression has been demonstrated after 6 months of treatment with Carvedilol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350490     DOI: 10.1007/bf00207616

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  34 in total

1.  [What value does echocardiography have in the assessment of left ventricular hypertrophy?].

Authors:  H Eichstädt; P Bubenheimer; B Ferber; H Riesterer
Journal:  Verh Dtsch Ges Kreislaufforsch       Date:  1977

2.  Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.

Authors:  H W Eichstädt; R Felix; M Langer; M L Gutmann; F C Dougherty; H J Huben; H Schmutzler
Journal:  Am J Cardiol       Date:  1987-04-24       Impact factor: 2.778

3.  Left ventricular hypertrophy as a risk factor.

Authors:  E D Frohlich
Journal:  Cardiol Clin       Date:  1986-02       Impact factor: 2.213

4.  Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats.

Authors:  B L Pegram; S Ishise; E D Frohlich
Journal:  Cardiovasc Res       Date:  1982-01       Impact factor: 10.787

5.  Precursors of sudden coronary death. Factors related to the incidence of sudden death.

Authors:  W B Kannel; J T Doyle; P M McNamara; P Quickenton; T Gordon
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

6.  Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy.

Authors:  F H Messerli; H O Ventura; D J Elizardi; F G Dunn; E D Frohlich
Journal:  Am J Med       Date:  1984-07       Impact factor: 4.965

Review 7.  Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy?

Authors:  E D Frohlich; R C Tarazi
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

8.  Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

9.  Time course of regression of left ventricular hypertrophy in treated hypertensive patients.

Authors:  G L Wollam; W D Hall; V D Porter; M B Douglas; D J Unger; B A Blumenstein; G A Cotsonis; M L Knudtson; J M Felner; R C Schlant
Journal:  Am J Med       Date:  1983-09-26       Impact factor: 4.965

10.  Disparate effects of methyldopa and clonidine on cardiac mass and haemodynamics in rats.

Authors:  S Ishise; B L Pegram; E D Frohlich
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

View more
  1 in total

Review 1.  Use of carvedilol in hypertension: an update.

Authors:  Gastone Leonetti; Colin G Egan
Journal:  Vasc Health Risk Manag       Date:  2012-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.